Daily Archives: February 8, 2019

Acute severe ulcerative colitis (ASUC) is a serious presentation of ulcerative colitis (UC) that carries a high risk for medical failure. First line therapy relies on IV corticosteroids, however up to 30% of patients will not respond. Even when second … Continue reading →

Thiopurines (TP) have been a historical mainstay in the treatment of pediatric IBD since the 1990s. However, the advent of anti-TNF therapy and increasing concerns about long-term safety of TP has prompted some clinicians to re-evaluate their role. DEV… Continue reading →

Malnutrition is highly prevalent in patients with inflammatory bowel disease (IBD). This preliminary study examined the effect of a nutrition support formula on blood nutrient parameters and explored effects on circulating blood cell counts and inflamm… Continue reading →

Pediatric Crohn’s disease poses challenges due to longer cumulative duration of disease and its effect on patient growth. A “top-down” approach, with early introduction of biologics, is common in pediatrics. Anti-TNF agents are commonly used, but… Continue reading →

Indigo naturalis (IN) is a traditional Chinese herbal medicine reported to be effective for inducing remission in ulcerative colitis (UC). We conducted a retrospective observational study to investigate the efficacy and safety of IN for inducing and ma… Continue reading →

Monitoring ustekinumab (UST) concentrations and antibodies-to ustekinumab (ATU) during IBD treatment may allow more informed decisions in assessing exposure/response and appropriate dosing. To aid in interpreting results in the context of Janssen’s p… Continue reading →

Therapeutic drug monitoring methods are lacking for methotrexate (MTX), an immunomodulator used in Inflammatory Bowel Disease (IBD) treatment, alone or in conjunction with infliximab (IFX). Although studies demonstrate a lack of relationship between MT… Continue reading →

Current evidence supports the use of reactive therapeutic drug monitoring (TDM) to guide treatment changes in inflammatory bowel disease (IBD) patients treated with anti-TNF agents. However, there is less data available on the utility of drug monitorin… Continue reading →

Current evidence supports the use of reactive therapeutic drug monitoring (TDM) to guide treatment changes in inflammatory bowel disease (IBD) patients treated with anti-TNF agents. However, there is less data available on the utility of drug monitorin… Continue reading →

Ulcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa. Infliximab has long been a standard therapy for moderate to severe UC. IV followed by oral cyclosporine (CsA) has demonstrated similar safety and efficacy to infliximab fo… Continue reading →